MicroRNA‑409‑5p inhibits cell proliferation, and induces G<sub>2</sub>/M phase arrest and apoptosis by targeting DLGAP5 in ovarian cancer cells

Li,Weiwei; Lin,Ji; Huang,Jianfen; Chen,Zhuoying; Sheng,Qunying; Yang,Fang; Yang,Xue; Cui,Xiaojie

doi:10.3892/ol.2022.13381

August-2022 Volume 24 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

August-2022 Volume 24 Issue 2

Full Size Image

Article Open Access

MicroRNA‑409‑5p inhibits cell proliferation, and induces G₂/M phase arrest and apoptosis by targeting DLGAP5 in ovarian cancer cells

Authors:
- Weiwei Li
- Ji Lin
- Jianfen Huang
- Zhuoying Chen
- Qunying Sheng
- Fang Yang
- Xue Yang
- Xiaojie Cui
View Affiliations / Copyright

Affiliations: Department of Gynecology, Mindong Hospital Affiliated to Fujian Medical University, Fuan, Fujian 355000, P.R. China, Department of Gynecology, Xiamen Fifth Hospital, Xiamen, Fujian 361101, P.R. China, Department of Clinical Medicine, Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China

Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Article Number: 261
|
Published online on: June 14, 2022

https://doi.org/10.3892/ol.2022.13381
Expand metrics +

Abstract

MicroRNA (miRNA/miR)‑409‑5p has been reported to be implicated in prostate and breast cancers; however, its functional role in ovarian cancer (OC) remains unclear. Therefore the aim of the present study was to investigate the clinical significance and biological function of miR‑409‑5p in OC. Here, reverse transcription‑quantitative PCR analysis was performed to detect miR‑409‑5p expression in OC tissues and cell lines. The association between miR‑409‑5p expression and the clinicopathological characteristics of patients with OC was assessed using the Fisher's exact test. Furthermore, the Cell Counting Kit‑8 assay was performed to assess cell proliferation. Cell cycle distribution and apoptosis were evaluated via flow cytometric analysis, and the target gene of miR‑409‑5p was validated via the dual‑luciferase reporter assay. The results demonstrated that miR‑409‑5p expression was significantly downregulated in OC tissues and cell lines compared with adjacent normal tissues and epithelial cells, respectively. In addition, low miR‑409‑5p expression was significantly associated with tumor size (P=0.044) and the International Federation of Gynecology and Obstetrics staging system (P=0.005). Notably, overexpression of miR‑409‑5p suppressed cell proliferation, and induced G2/M phase arrest and apoptosis of OC cells. Mechanistically, discs large‑associated protein 5 (DLGAP5) was identified as a novel target of miR‑409‑5p, which was negatively regulated by miR‑409‑5p. DLGAP5 expression was significantly upregulated in OC tissues and cell lines compared with adjacent normal tissues and epithelial cells, respectively. Furthermore, overexpression of DLGAP5 reversed the effects of miR‑409‑5p on SKOV‑3 cell proliferation, and G2/M phase and apoptosis. Taken together, these results suggest that miR‑409‑5p acts as a tumor suppressor in OC by modulating DLGAP5 expression.

View Figures

View References

1	Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A and Siegel RL: Ovarian cancer statistics, 2018. CA Cancer J Clin. 68:284–296. 2018. View Article : Google Scholar : PubMed/NCBI
2	Staicu CE, Predescu DV, Rusu CM, Radu BM, Cretoiu D, Suciu N, Crețoiu SM and Voinea SC: Role of microRNAs as clinical cancer biomarkers for ovarian cancer: A short overview. Cells. 9:1692020. View Article : Google Scholar : PubMed/NCBI
3	Tsujioka H, Yotsumoto F, Hikita S, Ueda T, Kuroki M and Miyamoto S: Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy. Curr Opin Obstet Gynecol. 23:24–30. 2011. View Article : Google Scholar : PubMed/NCBI
4	Pinato DJ, Graham J, Gabra H and Sharma R: Evolving concepts in the management of drug resistant ovarian cancer: Dose dense chemotherapy and the reversal of clinical platinum resistance. Cancer Treat Rev. 39:153–160. 2013. View Article : Google Scholar : PubMed/NCBI
5	Lu KH: Screening for ovarian cancer in asymptomatic women. Jama. 319:557–558. 2018. View Article : Google Scholar : PubMed/NCBI
6	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
7	Fabian MR, Sonenberg N and Filipowicz W: Regulation of mRNA translation and stability by microRNAs. Ann Rev Biochem. 79:351–379. 2010. View Article : Google Scholar : PubMed/NCBI
8	Krol J, Loedige I and Filipowicz W: The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 11:597–610. 2010. View Article : Google Scholar : PubMed/NCBI
9	Deb B, Uddin A and Chakraborty S: miRNAs and ovarian cancer: An overview. J Cell Physiol. 233:3846–3854. 2018. View Article : Google Scholar : PubMed/NCBI
10	Mandilaras V, Vernon M, Meryet-Figuiere M, Karakasis K, Lambert B, Poulain L, Oza A and Denoyelle C: Updates and current challenges in microRNA research for personalized medicine in ovarian cancer. Exp Opin Biol Ther. 17:927–943. 2017. View Article : Google Scholar : PubMed/NCBI
11	Zhou P, Xiong T, Yao L and Yuan J: MicroRNA-665 promotes the proliferation of ovarian cancer cells by targeting SRCIN1. Exp Ther Med. 19:1112–1120. 2020.PubMed/NCBI
12	Wang Y, Lei X, Gao C, Xue Y, Li X, Wang H and Feng Y: miR-506-3p suppresses the proliferation of ovarian cancer cells by negatively regulating the expression of MTMR6. J Biosci. 44:1262019. View Article : Google Scholar : PubMed/NCBI
13	Kavitha N, Vijayarathna S, Jothy SL, Oon CE, Chen Y, Kanwar JR and Sasidharan S: MicroRNAs: Biogenesis, roles for carcinogenesis and as potential biomarkers for cancer diagnosis and prognosis. Asian Pac J Cancer Prev. 15:7489–7497. 2014. View Article : Google Scholar : PubMed/NCBI
14	Galasso M, Sandhu SK and Volinia S: MicroRNA expression signatures in solid malignancies. Cancer J. 18:238–243. 2012. View Article : Google Scholar : PubMed/NCBI
15	Zheng B, Liang L, Huang S, Zha R, Liu L, Jia D, Tian Q, Wang Q, Wang C, Long Z, et al: MicroRNA-409 suppresses tumour cell invasion and metastasis by directly targeting radixin in gastric cancers. Oncogene. 31:4509–4516. 2012. View Article : Google Scholar : PubMed/NCBI
16	Josson S, Gururajan M, Hu P, Shao C, Chu GY, Zhau HE, Liu C, Lao K, Lu CL, Lu YT, et al: miR-409-3p/-5p promotes tumorigenesis, epithelial-to-mesenchymal transition, and bone metastasis of human prostate cancer. Clin Cancer Res. 20:4636–4646. 2014. View Article : Google Scholar : PubMed/NCBI
17	Yu H, Xing H, Han W, Wang Y, Qi T, Song C, Xu Z, Li H and Huang Y: MicroRNA-409-5p is upregulated in breast cancer and its downregulation inhibits cancer development through downstream target of RSU1. Tumour Biol. 39:10104283177016472017. View Article : Google Scholar : PubMed/NCBI
18	Zhang S, Lu Z, Unruh AK, Ivan C, Baggerly KA, Calin GA, Li Z, Bast RC Jr and Le XF: Clinically relevant microRNAs in ovarian cancer. Mol Cancer Res. 13:393–401. 2015. View Article : Google Scholar : PubMed/NCBI
19	Zhang S, Zhang X, Fu X, Li W, Xing S and Yang Y: Identification of common differentially-expressed miRNAs in ovarian cancer cells and their exosomes compared with normal ovarian surface epithelial cell cells. Oncol Lett. 16:2391–2401. 2018.PubMed/NCBI
20	Koffa MD, Casanova CM, Santarella R, Köcher T, Wilm M and Mattaj IW: HURP is part of a ran-dependent complex involved in spindle formation. Curr Biol. 16:743–754. 2006. View Article : Google Scholar : PubMed/NCBI
21	Schneider MA, Christopoulos P, Muley T, Warth A, Klingmueller U, Thomas M, Herth FJ, Dienemann H, Mueller NS, Theis F and Meister M: AURKA, DLGAP5, TPX2, KIF11 and CKAP5: Five specific mitosis-associated genes correlate with poor prognosis for non-small cell lung cancer patients. Int J Oncol. 50:365–372. 2017. View Article : Google Scholar : PubMed/NCBI
22	Shi YX, Yin JY, Shen Y, Zhang W, Zhou HH and Liu ZQ: Genome-scale analysis identifies NEK2, DLGAP5 and ECT2 as promising diagnostic and prognostic biomarkers in human lung cancer. Sci Rep. 7:80722017. View Article : Google Scholar : PubMed/NCBI
23	Weinberger P, Ponny SR, Xu H, Bai S, Smallridge R, Copland J and Sharma A: Cell cycle M-phase genes are highly upregulated in anaplastic thyroid carcinoma. Thyroid. 27:236–252. 2017. View Article : Google Scholar : PubMed/NCBI
24	Zhou Y, Yang L, Zhang X, Chen R, Chen X, Tang W and Zhang M: Identification of potential biomarkers in glioblastoma through bioinformatic analysis and evaluating their prognostic value. Biomed Res Int. 2019:65815762019. View Article : Google Scholar : PubMed/NCBI
25	Zhou Z, Cheng Y, Jiang Y, Liu S, Zhang M, Liu J and Zhao Q: Ten hub genes associated with progression and prognosis of pancreatic carcinoma identified by co-expression analysis. Int J Biol Sci. 14:124–136. 2018. View Article : Google Scholar : PubMed/NCBI
26	Branchi V, Garcia SA, Radhakrishnan P, Győrffy B, Hissa B, Schneider M, Reißfelder C and Schölch S: Prognostic value of DLGAP5 in colorectal cancer. Int J Colorectal Dis. 34:1455–1465. 2019. View Article : Google Scholar : PubMed/NCBI
27	Liao W, Liu W, Yuan Q, Liu X, Ou Y, He S, Yuan S, Qin L, Chen Q, Nong K, et al: Silencing of DLGAP5 by siRNA significantly inhibits the proliferation and invasion of hepatocellular carcinoma cells. PLoS One. 8:e807892013. View Article : Google Scholar : PubMed/NCBI
28	Kuo TC, Chang PY, Huang SF, Chou CK and Chao CCK: Knockdown of HURP inhibits the proliferation of hepacellular carcinoma cells via downregulation of gankyrin and accumulation of p53. Biochem Pharmacol. 83:758–768. 2012. View Article : Google Scholar : PubMed/NCBI
29	Zhang X, Pan Y, Fu H and Zhang J: Nucleolar and spindle associated protein 1 (NUSAP1) inhibits cell proliferation and enhances susceptibility to epirubicin in invasive breast cancer cells by regulating cyclin D kinase (CDK1) and DLGAP5 expression. Med Sci Monit. 24:8553–8564. 2018. View Article : Google Scholar : PubMed/NCBI
30	Zeppernick F and Meinhold-Heerlein I: The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. Arch Gynecol Obstet. 290:839–842. 2014. View Article : Google Scholar : PubMed/NCBI
31	Rosen DG, Yang G, Liu G, Mercado-Uribe I, Chang B, Xiao XS, Zheng J, Xue FX and Liu J: Ovarian cancer: Pathology, biology, and disease models. Front Biosci (Landmark Ed). 14:2089–2102. 2009. View Article : Google Scholar : PubMed/NCBI
32	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
33	Xu X, Chen H, Lin Y, Hu Z, Mao Y, Wu J, Xu X, Zhu Y, Li S, Zheng X and Xie L: MicroRNA-409-3p inhibits migration and invasion of bladder cancer cells via targeting c-met. Mol Cells. 36:62–68. 2013. View Article : Google Scholar : PubMed/NCBI
34	Wan L, Zhu L, Xu J, Lu B, Yang Y, Liu F and Wang Z: MicroRNA-409-3p functions as a tumor suppressor in human lung adenocarcinoma by targeting c-met. Cell Physiol Biochem. 34:1273–1290. 2014. View Article : Google Scholar : PubMed/NCBI
35	Bai R, Weng C, Dong H, Li S, Chen G and Xu Z: MicroRNA-409-3p suppresses colorectal cancer invasion and metastasis partly by targeting GAB1 expression. Int J Cancer. 137:2310–2322. 2015. View Article : Google Scholar : PubMed/NCBI
36	Zhang G, Liu Z, Xu H and Yang Q: miR-409-3p suppresses breast cancer cell growth and invasion by targeting Akt1. Biochem Biophys Res Commun. 469:189–195. 2016. View Article : Google Scholar : PubMed/NCBI
37	Cao GH, Sun XL, Wu F, Chen WF, Li JQ and Hu WC: Low expression of miR-409-3p is a prognostic marker for breast cancer. Eur Rev Med Pharmacol Sci. 20:3825–3829. 2016.PubMed/NCBI
38	Cao Y, Zhang L, Wei M, Jiang X and Jia D: MicroRNA-409-3p represses glioma cell invasion and proliferation by targeting high-mobility group nucleosome-binding domain 5. Oncol Res. 25:1097–1107. 2017. View Article : Google Scholar : PubMed/NCBI
39	Prakash R, John AA and Singh D: miR-409-5p negatively regulates Wnt/Beta catenin signaling pathway by targeting Lrp-8. J Cell Physiol. 234:23507–23517. 2019. View Article : Google Scholar : PubMed/NCBI
40	Li C, Nie H, Wang M, Su L, Li J, Yu B, Wei M, Ju J, Yu Y, Yan M, et al: MicroRNA-409-3p regulates cell proliferation and apoptosis by targeting PHF10 in gastric cancer. Cancer Lett. 320:189–197. 2012. View Article : Google Scholar : PubMed/NCBI
41	Zhang J, Hou W, Jia J, Zhao Y and Zhao B: miR-409-3p regulates cell proliferation and tumor growth by targeting E74-like factor 2 in osteosarcoma. FEBS Open Bio. 7:348–357. 2017. View Article : Google Scholar : PubMed/NCBI
42	Zhao Z, Yang F, Liu Y, Fu K and Jing S: MicroRNA-409-3p suppresses cell proliferation and cell cycle progression by targeting cyclin D2 in papillary thyroid carcinoma. Oncol Lett. 16:5237–5242. 2018.PubMed/NCBI
43	Ma Z, Li Y, Xu J, Ren Q, Yao J and Tian X: MicroRNA-409-3p regulates cell invasion and metastasis by targeting ZEB1 in breast cancer. IUBMB Life. 68:394–402. 2016. View Article : Google Scholar : PubMed/NCBI
44	Chen H and Dai J: miR-409-3p suppresses the proliferation, invasion and migration of tongue squamous cell carcinoma via targeting RDX. Oncol Lett. 16:543–551. 2018.PubMed/NCBI
45	Wu L, Zhang Y, Huang Z, Gu H, Zhou K, Yin X and Xu J: MiR-409-3p inhibits cell proliferation and invasion of osteosarcoma by targeting zinc-finger E-box-binding homeobox-1. Front Pharmacol. 10:1372019. View Article : Google Scholar : PubMed/NCBI
46	Santarella RA, Koffa MD, Tittmann P, Gross H and Hoenger A: HURP wraps microtubule ends with an additional tubulin sheet that has a novel conformation of tubulin. J Mol Biol. 365:1587–1595. 2007. View Article : Google Scholar : PubMed/NCBI
47	Hsu JM, Lee YC, Yu CT and Huang CY: Fbx7 functions in the SCF complex regulating Cdk1-cyclin B-phosphorylated hepatoma up-regulated protein (HURP) proteolysis by a proline-rich region. J Biol Chem. 279:32592–32602. 2004. View Article : Google Scholar : PubMed/NCBI
48	Di Leva G, Garofalo M and Croce CM: MicroRNAs in cancer. Ann Rev Pathol. 9:287–314. 2014. View Article : Google Scholar : PubMed/NCBI
49	Ganju A, Khan S, Hafeez BB, Behrman SW, Yallapu MM, Chauhan SC and Jaggi M: miRNA nanotherapeutics for cancer. Drug Discov Today. 22:424–432. 2017. View Article : Google Scholar : PubMed/NCBI
50	Hayes J, Peruzzi PP and Lawler S: MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
51	Bader AG, Brown D and Winkler M: The promise of microRNA replacement therapy. Cancer Res. 70:7027–7030. 2010. View Article : Google Scholar : PubMed/NCBI

Journals